Patents by Inventor Stefan Jacobs

Stefan Jacobs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20240091312
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: August 24, 2023
    Publication date: March 21, 2024
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll, Stefan Jacobs, Cornelia Heinz
  • DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS
    Publication number: 20240059772
    Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
    Type: Application
    Filed: June 22, 2023
    Publication date: February 22, 2024
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Meike Wagner, Maria Kreuzberg, Sabine Hacker, Stefan Jacobs
  • Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
    Patent number: 11826402
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: November 28, 2023
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsm
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Diagnosis and therapy of cancer involving cancer stem cells
    Patent number: 11795218
    Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: October 24, 2023
    Assignees: BioNTech AG, Astellas Pharma Inc., TRON—Translationale Onkologie an der Universität
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Meike Wagner, Maria Kreuzberg, Sabine Hacker, Stefan Jacobs
  • DRUG CONJUGATES COMPRISING ANTIBODIES AGAINST CLAUDIN 18.2
    Publication number: 20230270878
    Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: August 31, 2023
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
  • Drug conjugates comprising antibodies against claudin 18.2
    Patent number: 11541127
    Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: January 3, 2023
    Assignees: Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
  • Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
    Patent number: 10946069
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 16, 2021
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20210023177
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS
    Publication number: 20200385460
    Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
    Type: Application
    Filed: February 19, 2020
    Publication date: December 10, 2020
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Meike Wagner, Maria Kreuzberg, Sabine Hacker, Stefan Jacobs
  • Diagnosis and therapy of cancer involving cancer stem cells
    Patent number: 10604568
    Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 31, 2020
    Assignees: BioN Tech AG, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, Astellas Pharma Inc.
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Meike Wagner, Maria Kreuzberg, Sabine Hacker, Stefan Jacobs
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20190298803
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 3, 2019
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
    Patent number: 10314890
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 11, 2019
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • DRUG CONJUGATES COMPRISING ANTIBODIES AGAINST CLAUDIN 18.2
    Publication number: 20180117174
    Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Application
    Filed: April 13, 2016
    Publication date: May 3, 2018
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20180000900
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: August 23, 2017
    Publication date: January 4, 2018
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
    Patent number: 9770487
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: September 26, 2017
    Assignees: Ganymed Pharmaceuticals AG, TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gGmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS
    Publication number: 20160159901
    Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
    Type: Application
    Filed: July 30, 2014
    Publication date: June 9, 2016
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Meike Wagner, Maria Kreuzberg, Sabine Hacker, Stefan Jacobs
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20150374789
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: February 18, 2014
    Publication date: December 31, 2015
    Applicants: GANYMED PHARMACEUTICALS AG, TRON-Translationale Onkologie an der Universitats- medizin der Johannes Gutenberg-Universitat Mainz.
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Muffler
    Patent number: 5581056
    Abstract: A muffler having an inner shell of two deep-drawn inner sheet metal plates laid one atop the other and a housing shell of at least two deep-drawn outer sheet metal plates laid one atop the other. The inner shell has an encircling edge while the housing shell has an encircling housing flange with a lock seam connection which seals the housing shell. The edge of the inner shell is designed so that it barely touches the wall of the housing shell and is held in a spring-like fashion only between clamping creases of the housing shell.
    Type: Grant
    Filed: January 20, 1995
    Date of Patent: December 3, 1996
    Assignee: Heinrich Gillet GmbH & Co. KG
    Inventors: Klaus Bellgardt, Stefan Jacobs, Gert Becker